• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性心肌梗死溶栓治疗期间凝血酶水平升高。对治疗成功的意义。

Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.

作者信息

Gulba D C, Barthels M, Westhoff-Bleck M, Jost S, Rafflenbeul W, Daniel W G, Hecker H, Lichtlen P R

机构信息

Division of Cardiology, Hannover Medical School, FRG.

出版信息

Circulation. 1991 Mar;83(3):937-44. doi: 10.1161/01.cir.83.3.937.

DOI:10.1161/01.cir.83.3.937
PMID:1900225
Abstract

BACKGROUND

It has been suggested that thrombolysis in a feedback reaction may generate pro-coagulant activities.

METHODS AND RESULTS

Fifty-five patients were treated with urokinase-preactivated prourokinase (n = 35) or tissue-type plasminogen activator (n = 20) for acute myocardial infarction and underwent coronary angiography at 90 minutes and at 24-36 hours into thrombolysis, and fibrinogen (Ratnoff-Menzie), D-dimer (ELISA) and thrombin-antithrombin III complex levels (ELISA) were measured. Primary patency was achieved in 39 patients (70.9%), 13 of whom (33.3%) suffered early reocclusion. Nonsignificant decreases in fibrinogen levels were observed while D-dimer levels increased +3,008 +/- 4,047 micrograms/l (p less than 0.01), differences not being significant in respect to the thrombolytic agents or to the clinical course. In contrast, while thrombin-antithrombin III complex levels decreased -4.4 +/- 13.0 micrograms/l in patients with persistent patency, they increased +7.5 +/- 13.6 micrograms/l in case of nonsuccessful thrombolysis (p less than 0.02) and +11.9 +/- 23.8 micrograms/l in case of early reocclusion (p less than 0.001). For patients with thrombin-antithrombin III complex levels greater than 6 ng/l 120 minutes into thrombolysis, the unfavorable clinical course was predicted with 96.2% sensitivity and 93.1% specificity.

CONCLUSION

Generation of thrombin, occurring during thrombolysis, is a major determinant for the success of therapy and thrombin-antithrombin III levels may serve as predictors for the short-term prognosis.

摘要

背景

有观点认为,反馈反应中的溶栓可能会产生促凝血活性。

方法与结果

55例急性心肌梗死患者接受尿激酶预激活的纤溶酶原(35例)或组织型纤溶酶原激活剂(20例)治疗,并在溶栓开始后90分钟以及24 - 36小时进行冠状动脉造影,同时测定纤维蛋白原(Ratnoff - Menzie法)、D - 二聚体(ELISA法)和凝血酶 - 抗凝血酶III复合物水平(ELISA法)。39例患者(70.9%)实现了初始血管通畅,其中13例(33.3%)出现早期再闭塞。纤维蛋白原水平有不显著下降,而D - 二聚体水平升高了3008±4047微克/升(p<0.01),这一差异在溶栓药物及临床病程方面并无显著意义。相比之下,持续血管通畅的患者凝血酶 - 抗凝血酶III复合物水平下降了4.4±13.0微克/升,溶栓未成功的患者该水平升高了7.5±13.6微克/升(p<0.02),早期再闭塞的患者升高了11.9±23.8微克/升(p<0.001)。对于溶栓120分钟时凝血酶 - 抗凝血酶III复合物水平大于6纳克/升的患者,预测不良临床病程的敏感度为96.2%,特异度为93.1%。

结论

溶栓过程中产生的凝血酶是治疗成功的主要决定因素,凝血酶 - 抗凝血酶III水平可作为短期预后的预测指标。

相似文献

1
Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.急性心肌梗死溶栓治疗期间凝血酶水平升高。对治疗成功的意义。
Circulation. 1991 Mar;83(3):937-44. doi: 10.1161/01.cir.83.3.937.
2
Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
Chin Med Sci J. 2002 Mar;17(1):36-9.
3
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.强化血小板聚集作为急性心肌梗死溶栓后再闭塞的预测指标
Thromb Haemost. 1998 Dec;80(6):881-6.
4
Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.急性心肌梗死溶栓治疗后凝血活性的系列变化
Angiology. 1994 Apr;45(4):273-81. doi: 10.1177/000331979404500403.
5
Role of thrombolysis and thrombin in patients with acute coronary occlusion during percutaneous transluminal coronary angioplasty.溶栓和凝血酶在经皮腔内冠状动脉成形术期间急性冠状动脉闭塞患者中的作用。
J Am Coll Cardiol. 1990 Sep;16(3):563-8. doi: 10.1016/0735-1097(90)90343-n.
6
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Circulation. 1990 Mar;81(3):907-13. doi: 10.1161/01.cir.81.3.907.
7
Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.急性心肌梗死中使用前尿激酶的冠状动脉再灌注研究:低剂量尿激酶协同作用的证据。
J Am Coll Cardiol. 1990 Sep;16(3):733-8. doi: 10.1016/0735-1097(90)90367-x.
8
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Am J Cardiol. 1991 Jun 15;67(16):1349-53. doi: 10.1016/0002-9149(91)90464-v.
9
Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.急性心肌梗死的序贯联合溶栓治疗:尿激酶原与组织型纤溶酶原激活剂增强溶栓作用(PATENT)试验结果
J Am Coll Cardiol. 1995 Aug;26(2):374-9. doi: 10.1016/0735-1097(95)80009-6.
10
New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.用于治疗急性心肌梗死患者的新型重组糖基化尿激酶原。尿激酶原研究组。
J Am Coll Cardiol. 1994 Nov 1;24(5):1242-8. doi: 10.1016/0735-1097(94)90105-8.

引用本文的文献

1
Enhanced thrombin and plasmin generation profiles in alpha-2-antiplasmin-deficient patients: Data from the Rare Bleeding disorders in the Netherlands study.α-2-抗纤溶酶缺乏患者凝血酶和纤溶酶生成增强情况:来自荷兰罕见出血性疾病研究的数据
Res Pract Thromb Haemost. 2024 Oct 23;8(7):102604. doi: 10.1016/j.rpth.2024.102604. eCollection 2024 Oct.
2
Enhanced Thrombin Generation Is Associated with Worse Left Ventricular Scarring after ST-Segment Elevation Myocardial Infarction: A Cohort Study.增强的凝血酶生成与ST段抬高型心肌梗死后更严重的左心室瘢痕形成相关:一项队列研究。
Pharmaceuticals (Basel). 2022 Jun 6;15(6):718. doi: 10.3390/ph15060718.
3
Nanozymes-Hitting the Biosensing "Target".
纳米酶——命中生物传感“靶点”。
Sensors (Basel). 2021 Jul 31;21(15):5201. doi: 10.3390/s21155201.
4
No effect of tranexamic acid on platelet function and thrombin generation (ETAPlaT) in postpartum haemorrhage: a randomised placebo-controlled trial.氨甲环酸对产后出血患者血小板功能及凝血酶生成的影响(ETAPlaT):一项随机安慰剂对照试验
Wellcome Open Res. 2019 Feb 5;4:21. doi: 10.12688/wellcomeopenres.14977.1. eCollection 2019.
5
Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK.小剂量组织型纤溶酶原激活剂(tPA)与低剂量突变型尿激酶原(proUK)序贯协同组合实现高效纤维蛋白溶解。
PLoS One. 2015 Mar 26;10(3):e0122018. doi: 10.1371/journal.pone.0122018. eCollection 2015.
6
Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study.急性心脑血管意外和中风溶栓治疗后自发性冠状动脉血栓形成:病例研究。
J Thromb Thrombolysis. 2012 Nov;34(4):548-51. doi: 10.1007/s11239-012-0754-2.
7
Current status of thrombolytic therapy in acute myocardial infarction.急性心肌梗死溶栓治疗的现状
Tex Heart Inst J. 1991;18(4):250-62.
8
Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.阿昔单抗和替罗非班不同溶栓治疗方案对血小板聚集及血小板-白细胞相互作用的影响:来自GUSTO V和FASTER试验的亚组分析
J Thromb Thrombolysis. 2002 Dec;14(3):197-203. doi: 10.1023/a:1025044625487.
9
Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.
Curr Cardiol Rep. 2002 Jul;4(4):313-9. doi: 10.1007/s11886-002-0067-8.
10
Platelet activation in acute myocardial infarction and the rationale for combination therapy.急性心肌梗死中的血小板活化及联合治疗的理论依据
Curr Cardiol Rep. 2000 Sep;2(5):378-85. doi: 10.1007/s11886-000-0050-1.